← Back to Search

Behavioural Intervention

SMS Chatbot Support for Gastrointestinal Cancer

N/A

Recruiting

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Capecitabine ONLY

Capecitabine concurrent with Radiation Therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 month

Awards & highlights

Study Summary

This trial is studying a new way to give people capecitabine, an oral chemotherapy. In the new way, people would take their capecitabine at home and check in with their doctor remotely to make sure they are taking the right dose and managing any side effects.

Who is the study for?

This trial is for patients with gastrointestinal cancers who are taking oral chemotherapy, specifically capecitabine alone or in combination with other treatments like oxaliplatin, temozolomide, radiation therapy, or mitomycin.Check my eligibility

What is being tested?

'Penny' is a chatbot delivered via the Memora Platform designed to help these patients manage their medication schedules and side effects. The study aims to improve adherence to complex oral chemotherapy regimens and better handle toxicity by providing remote guidance and monitoring.See study design

What are the potential side effects?

While 'Penny' itself doesn't cause side effects, it helps manage those from oral chemotherapies like capecitabine which can include digestive issues, fatigue, hand-foot syndrome (redness/pain/swelling of hands/feet), and blood count changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 month

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 month

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Medication Compliance - Will assess accuracy of medication reminders to patients and patient adherence to prescribed medication dosing and schedule

Patient Engagement with the Penny chatbot

Patient Safety of the Patient - Penny Chatbot interactions with patients will be assessed for accuracy of medication directions and triaging of symptoms reported and number of incorrect interactions between Penny and Patients will be measured.

Secondary outcome measures

Patient Satisfaction with the Penny chatbot interactions will be measured by the Promoter Score

Trial Design

1Treatment groups

Experimental Treatment

Group I: Penny, a SMS Text-based chatbot interventionExperimental Treatment1 Intervention

This is a single arm study. All recruited patients will be entered on the Penny SMS Text-based chatbot intervention.

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

104,955 Total Patients Enrolled

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,555 Total Patients Enrolled

Media Library

'Penny' via Memora Platform (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05113264 — N/A

Gastrointestinal Cancer Research Study Groups: Penny, a SMS Text-based chatbot intervention

Gastrointestinal Cancer Clinical Trial 2023: 'Penny' via Memora Platform Highlights & Side Effects. Trial Name: NCT05113264 — N/A

'Penny' via Memora Platform (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05113264 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants has this clinical trial enrolled to date?

"Affirmative. Clinicaltrials.gov has data that suggests this medical trial is currently seeking participants, which was initially posted on August 2nd 2021 and most recently amended on November 18th 2022. The research requires 140 individuals to join at 1 site."

Answered by AI

Does this experiment have vacancies for participants?

"Affirmative. According to clinicaltrials.gov, recruitment for this trial is ongoing as of November 18th 2022. This research effort was first published on August 2nd 2021 and seeks 140 patients from a single centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

'Penny', a SMS Text-based Chatbot Intervention for Medication Adherence and Side Effect Management Among Patients With GI Cancers

2021. "'Penny', a SMS Text-based Chatbot Intervention for Medication Adherence and Side Effect Management Among Patients With GI Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05113264.